NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Sai Parenterals FY26 Consolidated Revenue Hits ₹381 Cr; Standalone PAT Jumps 64% YoY
Sai Parenterals reported a strong performance for FY26, with consolidated revenue reaching ₹381 crore, significantly aided by the acquisition of Australia-based Noumed Pharmaceuticals. On a standalone basis, the company saw a robust 64% YoY growth in PAT to ₹17 crore, driven by a massive 250% surge in CDMO revenue. The company successfully listed in April 2026 after a ₹285 crore IPO, utilizing funds for capacity expansion and R&D. With 67 dossiers currently under development and a new facility in Adelaide on track for Q4FY27, the company is aggressively targeting regulated markets.
முக்கிய அம்சங்கள்
Consolidated FY26 revenue reached ₹381 crore, with Q4FY26 contributing ₹198 crore following the Noumed consolidation.Standalone PAT grew 64% YoY to ₹17 crore, while standalone EBITDA increased 23% to ₹33 crore.CDMO revenue surged by over 250% YoY, reflecting deeper engagement with global customers and long-term contracts.Expanded portfolio by 93 dossiers in FY26, with 67 additional dossiers currently under development for export-led growth.Investing ₹111 crore in Unit III expansion and AUD 53 million for a new TGA-approved facility in Australia.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful integration of Noumed and the ramp-up of the CDMO business which is driving higher margins. The progress of the Adelaide facility and EU-GMP upgradations of Indian units are key catalysts for future valuation re-rating.
Amara Raja Q4 Revenue Grows 16% to ₹3,460 Cr; Recommends ₹5.2 Final Dividend
Amara Raja Energy & Mobility (ARE&M) reported a 16% YoY revenue growth in Q4 FY26, reaching ₹3,460 Cr, while Q4 PBT nearly doubled to ₹433 Cr. For the full year FY26, revenue stood at ₹13,549 Cr with a profit before tax of ₹1,307 Cr and an EPS of ₹53.02. The company's new energy business is scaling rapidly, posting a 60% revenue increase, and the board has recommended a final dividend of ₹5.2 per share. Strategic projects like the Giga Corridor and BESS plant are on track, with the R&D center becoming operational next month.
முக்கிய அம்சங்கள்
Q4 FY26 revenue rose 16% YoY to ₹3,460 Cr; Q4 PBT jumped to ₹433 Cr from ₹224 Cr.Full-year FY26 revenue reached ₹13,549 Cr compared to ₹12,405 Cr in FY25.New energy business revenue surged by 60% YoY, driven by lithium solutions and telecom expansion.Board recommended a final dividend of ₹5.2 per share for FY26.2 GWh cell manufacturing capacity remains on track for commissioning by June 2027.
👀 கவனிக்க வேண்டியவை
The stock remains a strong play on the energy transition, with the new energy segment showing high growth potential. Investors should monitor the progress of the Giga factory and the impact of lead price volatility on core margins.
Amara Raja Energy & Mobility Announces ₹5.20 Final Dividend; Sets Record Date for July 27, 2026
Amara Raja Energy & Mobility Limited (ARE&M) has announced a final dividend of ₹5.20 per equity share for the financial year 2025-26, representing a 520% payout on the face value of ₹1. The company has fixed July 27, 2026, as the record date to determine shareholder eligibility for this payout. Additionally, the 41st Annual General Meeting (AGM) is scheduled to be held on August 10, 2026. This announcement provides clarity on the timing and quantum of the final return to shareholders for the previous fiscal year.
முக்கிய அம்சங்கள்
Final dividend declared at ₹5.20 per equity share of ₹1 face value (520%)Record date for dividend eligibility fixed as Monday, July 27, 202641st Annual General Meeting (AGM) scheduled for Monday, August 10, 2026The dividend pertains to the financial year ending March 31, 2026
👀 கவனிக்க வேண்டியவை
Investors seeking to benefit from the ₹5.20 dividend should ensure they own the stock before the ex-dividend date, which is typically one business day prior to the July 27 record date.
Amara Raja Q4 FY26 Net Profit Surges to ₹322 Cr; Final Dividend of ₹5.20 Declared
Amara Raja Energy & Mobility Limited (ARE&M) reported a robust performance for Q4 FY26, with revenue from operations rising to ₹3,459.92 crore from ₹2,973.85 crore YoY. Net profit for the quarter nearly doubled to ₹322.33 crore, supported by an exceptional gain of ₹181.15 crore. For the full fiscal year 2025-26, the company achieved a total revenue of ₹13,548.86 crore and a net profit of ₹970.43 crore. The board has recommended a final dividend of ₹5.20 per share, bringing the total dividend for the year to ₹10.60.
முக்கிய அம்சங்கள்
Q4 FY26 revenue from operations grew 16.3% YoY to ₹3,459.92 crore.Net profit for Q4 FY26 stood at ₹322.33 crore compared to ₹166.81 crore in the previous year.Full-year FY26 revenue reached ₹13,548.86 crore with a consolidated net profit of ₹970.43 crore.Recommended a final dividend of ₹5.20 per share (520%), totaling ₹10.60 for the full year.Earnings per share (EPS) for Q4 FY26 increased significantly to ₹17.61 from ₹9.11 YoY.
👀 கவனிக்க வேண்டியவை
Investors should view the steady revenue growth and high dividend payout favorably, though the bottom line was boosted by exceptional items. The company's transition towards energy and mobility solutions continues to reflect in its scale.
Sai Parenterals Q4 PAT Surges 736% to ₹13.25 Cr; FY27 Revenue Target Set at ₹750 Cr
Sai Parenterals reported an exceptional Q4 FY26 with PAT surging 736% YoY to ₹13.25 crore, driven by the successful integration of Noumed (Australia) and a 250% jump in CDMO revenues. Full-year FY26 revenue grew 140% to ₹380.99 crore, reflecting the impact of strategic acquisitions and export growth. The company successfully completed its IPO in March 2026, raising ₹285 crore to fund a massive ₹440 crore capex program. Management has issued aggressive guidance for FY27, targeting ₹750 crore in revenue and an improved EBITDA margin of 17%.
முக்கிய அம்சங்கள்
Q4 FY26 revenue grew 166.65% YoY to ₹197.93 Cr, while PAT increased 736.04% to ₹13.25 Cr.FY26 consolidated revenue reached ₹380.99 Cr (+140.37% YoY) following the acquisition of Noumed Australia.Management targets FY27 revenue of ₹750 Cr and EBITDA margins of 17%, nearly doubling current revenue levels.Ongoing capex of ₹440 Cr includes a new R&D center in India and Australia's largest modern pharmaceutical plant.CDMO revenues surged by over 250% YoY, supported by 88 new product dossiers added in FY26 and 67 more in the pipeline.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to execute its ₹440 crore capex and achieve the ambitious ₹750 crore revenue target for FY27. The stock remains a high-growth play in the CDMO and injectable space following its recent listing and successful Australian integration.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Sai Parenterals Reports Zero Deviation in Utilization of ₹2,850 Million IPO Proceeds
Sai Parenterals Limited has submitted its statement of deviation for the quarter and year ended March 31, 2026, confirming that IPO funds are being handled as per the offer document. The company raised ₹2,850 million through its Initial Public Offer in late March 2026. As of the reporting date, no funds have been diverted from their original objects, which include significant allocations for capacity expansion and debt repayment. The monitoring agency, India Ratings & Research, and the company's Audit Committee have reviewed and confirmed the status.
முக்கிய அம்சங்கள்
Successfully raised ₹2,850 million through an IPO conducted between March 24 and March 27, 2026.Confirmed zero deviation or variation in the utilization of proceeds for the period ending March 31, 2026.Major allocations include ₹1,107.95 million for capacity expansion and ₹356.41 million for loan repayments related to the acquisition of Noumed Pharmaceuticals (Australia).Allocated ₹180.23 million for the establishment of a new R&D Centre and ₹330 million for working capital requirements.India Ratings & Research Private Limited is acting as the monitoring agency for the fund utilization.
👀 கவனிக்க வேண்டியவை
Investors should track subsequent quarterly filings to ensure the ₹2,850 million is deployed timely into the high-growth capacity expansion and R&D projects as promised.
Sai Parenterals Reports Q3 FY26 Consolidated PAT of ₹33.37 Million Post-IPO
Sai Parenterals Limited has released its first set of financial results post-listing for the quarter and nine months ended December 31, 2025. On a consolidated basis, the company reported a revenue of ₹892.11 million for the quarter, though it faced a loss before tax of ₹16.25 million, which turned into a PAT of ₹33.37 million due to deferred tax credits. The standalone performance remained profitable with a nine-month PAT of ₹68.28 million. A significant development is the completed acquisition of a 74.64% stake in UK-based Noumed Life Sciences for AUD 22 million, which is now reflected in the consolidated figures.
முக்கிய அம்சங்கள்
Consolidated Revenue from Operations for Q3 FY26 stood at ₹892.11 million.Consolidated Profit After Tax (PAT) for the quarter was ₹33.37 million, supported by a ₹55.57 million deferred tax credit.Standalone Nine-Month revenue reached ₹1,054.59 million with a PAT of ₹68.28 million.Completed acquisition of 74.64% stake in Noumed Life Sciences Limited (UK) for an aggregate consideration of AUD 22 million.The company reported an unmodified audit opinion for the financial year ended March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the operational integration of the UK-based Noumed Life Sciences, as the consolidated entity is currently reporting losses at the pre-tax level despite high revenue scaling. The stock's performance will likely depend on the company's ability to turn the consolidated operations profitable without relying on tax adjustments.
Sai Parenterals Q3 FY26 Consolidated Revenue at ₹892.1M; Completes Noumed UK Acquisition
Sai Parenterals reported a consolidated revenue of ₹892.11 million for the quarter ended December 31, 2025, with a net profit of ₹33.37 million. The standalone performance for the same quarter showed a revenue of ₹384.79 million and a profit of ₹3.63 million. A major strategic milestone was the completion of a 74.64% stake acquisition in UK-based Noumed Life Sciences Limited for AUD 22 million. As the company was recently listed, year-on-year comparative figures for the previous financial year are not available.
முக்கிய அம்சங்கள்
Consolidated revenue for Q3 FY26 reached ₹892.11 million with a PAT of ₹33.37 million.Standalone 9-month revenue stood at ₹1,054.59 million with a PAT of ₹68.28 million.Completed acquisition of 74.64% stake in Noumed Life Sciences (UK) for a total consideration of AUD 22 million.Consolidated 9-month revenue reported at ₹1,530.71 million, indicating strong contribution from international subsidiaries.Statutory auditors issued an unmodified opinion on the audited financial results for the year ended March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration of the Noumed UK acquisition and its impact on consolidated margins in future quarters. As a newly listed entity, focus on the company's ability to maintain revenue growth in the branded generic and CDMO segments.
Share India Appoints Former CBDT Chairman Arun Kumar Jain as Independent Director for 5 Years
Share India Securities has received shareholder approval via postal ballot for key board appointments. Mr. Arun Kumar Jain, a former Chairman of the Central Board of Direct Taxes (CBDT), has been appointed as a Non-Executive Independent Director for a five-year term starting March 05, 2026. Additionally, Mr. Piyush Mahesh Khandelwal has been re-appointed as an Independent Director for another five-year term effective March 03, 2026. These appointments are aimed at strengthening the company's governance framework and regulatory oversight.
முக்கிய அம்சங்கள்
Appointment of Mr. Arun Kumar Jain as Independent Director for a 5-year term starting March 05, 2026Mr. Jain is a former Chairman of the CBDT with extensive experience in taxation and financeRe-appointment of Mr. Piyush Mahesh Khandelwal as Independent Director for a second 5-year termApproval obtained via Postal Ballot with voting concluding on May 21, 2026
👀 கவனிக்க வேண்டியவை
The inclusion of a high-profile former tax official on the board enhances the company's corporate governance profile. Investors should view this as a positive step for long-term institutional stability.
Share India Q4 FY26 Consolidated PAT Surges 220% to ₹58 Cr; PMS AUM Crosses ₹100 Cr
Share India Securities reported a robust Q4 FY26 with consolidated revenue rising 74% YoY to ₹416 crore and PAT jumping 220% to ₹58 crore. While full-year consolidated PAT remained flat at ₹324 crore due to fair value adjustments, standalone performance was exceptionally strong with FY26 PAT growing 20% to ₹298 crore. The company is successfully diversifying into Wealth Management, with its PMS already reaching ₹100 crore AUM and a target of ₹200 crore for FY27. Additionally, the new debt market vertical, Share India Cred, has already closed six issues and targets ₹500 crore in volume for the coming year.
முக்கிய அம்சங்கள்
Standalone Q4 revenue grew 103% YoY to ₹383 crore, with standalone PAT up 368% to ₹75 crore.Consolidated net worth stands strong at ₹2,655 crore as of March 31, 2026.The uTrade algo-trading platform reached a significant milestone of 5,231 retail clients.New debt market vertical 'Share India Cred' launched in Q1 FY27 with a target of ₹500 crore in issues.Applied for AIF CAT-3 license with SEBI, expecting approval and operations to commence by Q2/Q3 FY27.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's successful transition from a pure brokerage to a diversified financial services firm with high-growth verticals like Wealth Management and Debt Markets. The strong Q4 recovery and scaling of the uTrade platform provide a positive outlook for FY27.
Saregama Q4FY26: Revenue up 19% to ₹287 Cr; Adjusted EBITDA grows 31% YoY
Saregama reported a strong Q4FY26 with revenue growing 19% YoY to INR 287 crores and adjusted EBITDA rising 31% to INR 133 crores. The music vertical, which includes licensing and artist management, saw 17% annual revenue growth, supported by the success of the 'Dhurandhar 1' album and the stabilization of streaming revenues. The company completed a strategic investment in Bhansali Productions to secure high-quality Hindi film music for the next 2-3 years. Additionally, Pocket Aces achieved breakeven, and the company is expanding its artist management portfolio to over 300 artists.
முக்கிய அம்சங்கள்
Q4 Revenue grew 19% YoY to INR 287 crores; Adjusted EBITDA rose 31% to INR 133 crores.Music vertical FY26 revenue reached INR 814 crores with a 22% YoY EBITDA growth.Invested INR 235 crores in new content and INR 105 crores in inorganic catalogue acquisitions in FY26.Strategic minority stake in Bhansali Productions ensures exclusive access to marquee music for 24-30 months.Pocket Aces reached breakeven; Artist management vertical now handles 300+ artists with 400M+ followers.
👀 கவனிக்க வேண்டியவை
Investors should view the strong EBITDA growth and strategic tie-up with Bhansali Productions as positive indicators of a long-term content moat. Monitor the transition to paid music subscriptions in India as a key future revenue driver for the company.
Thyrocare Promoter Docon Technologies Reports 60.93% Total Shareholding Pledged in FY26 Disclosure
Docon Technologies, the promoter of Thyrocare, has filed its annual disclosure under SEBI Takeover Regulations for the financial year ended March 31, 2026. The filing confirms that the promoter's entire 60.93% stake in the company remains encumbered. Notable activity during the year included a pledge modification following a 2:1 bonus issue in December 2025, which brought the total pledged shares to 9,69,69,696. This disclosure is a routine compliance measure to ensure transparency regarding promoter share encumbrances.
முக்கிய அம்சங்கள்
Promoter Docon Technologies and API Holdings confirm 60.93% of total share capital is pledged.A 2:1 bonus issue in December 2025 led to the encumbrance of 6.46 crore additional shares.The total number of shares under pledge stands at 9,69,69,696 as of March 31, 2026.The filing confirms no new undisclosed encumbrances were created during the 2025-26 financial year.
👀 கவனிக்க வேண்டியவை
Monitor the high promoter pledge (100% of their stake) as a risk factor for potential volatility. No immediate action is needed as this is a routine regulatory confirmation of existing encumbrances.
Share India Q4 PAT Surges 211% to ₹58 Cr; FY26 Revenue Hits ₹1,470 Cr
Share India Securities reported a robust Q4-FY26 with revenue growing 73.7% YoY to ₹415.9 crore and PAT jumping 211.3% to ₹58 crore. For the full year FY26, revenue remained stable at ₹1,470.3 crore, though PAT saw a marginal decline of 1.1% to ₹324.4 crore. The company is successfully transitioning to a fintech-led model, with its uTrade Algos platform reaching over 71,000 subscriptions. A final dividend of ₹0.50 per share was recommended, bringing the total FY26 payout to ₹1.60 per share.
முக்கிய அம்சங்கள்
Q4-FY26 PAT grew 211.3% YoY to ₹580 Mn with EBITDA margins expanding 626 bps to 28.11%Full-year FY26 revenue reached ₹14,703 Mn with a 6-year revenue CAGR of 37%MTF AUM stood at ₹4,239 Mn and NBFC AUM at ₹2,653 Mn as of March 31, 2026Recommended final dividend of ₹0.50 per share, totaling ₹1.60 for the full financial yearExpanding into AIF, PMS, and fixed-income distribution through newly incorporated subsidiaries
👀 கவனிக்க வேண்டியவை
The strong Q4 recovery and expansion into high-margin AIF and PMS segments are positive indicators; investors should monitor the adoption rate of the uTrade Algos platform.
Share India Q4 Net Profit Surges 211% YoY to ₹580 Mn; Final Dividend Announced
Share India Securities reported a massive 211.3% YoY jump in Q4 FY26 net profit to ₹580 million, driven by a 73.7% revenue growth. While the full-year FY26 net profit saw a marginal decline of 1.1% to ₹3,244 million, the Q4 performance indicates a strong recovery and growth momentum. The company is aggressively diversifying its portfolio, having recently incorporated subsidiaries for fixed-income distribution and AIF/PMS services. Additionally, the board has recommended a final dividend of ₹0.50 per share.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue grew 73.7% YoY to ₹4,159 Mn, with EBITDA surging 123.2% to ₹1,169 Mn.Full-year FY26 Net Profit stood at ₹3,244 Mn, a slight 1.1% decline YoY despite a 10.3% rise in EBITDA.NBFC loan book reached ₹2,653 Mn with quarterly disbursements of ₹995 Mn across 73 branches.Broking business recorded an average daily turnover of ₹109 Bn for the quarter ended March 2026.Board recommended a final dividend of ₹0.50 per share on shares with a face value of ₹2.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong Q4 recovery and the company's strategic expansion into AIF and PMS segments which could drive future margins. The stock remains a key play in the technology-driven brokerage and algo-trading space with a healthy dividend yield.
Hindware Home Innovation FY26 Revenue at ₹2,193 Cr; Bathware EBITDA Grows 30% YoY
Hindware Home Innovation reported a consolidated revenue of ₹2,193 crore for FY26, with the core Bathware segment contributing ₹1,520 crore, a 10% YoY growth. The Bathware business showed strong operational efficiency as EBITDA surged 30% YoY to ₹157 crore, with margins expanding from 8.8% to 10.3%. The company is progressing with a major corporate restructuring to demerge its Consumer Products business into HHIL Limited and amalgamate the rest into Hindware Limited, aiming to unlock stakeholder value. Management has issued a positive outlook for FY27, targeting 15-20% sales growth in the Bathware segment.
முக்கிய அம்சங்கள்
Consolidated FY26 revenue stood at ₹2,193 crore with an improved EBITDA margin of 9%.Bathware segment revenue grew 10% to ₹1,520 crore, while its EBITDA jumped 30% to ₹157 crore.Net bank debt was reduced to ₹664 crore in FY26 from ₹693 crore in the previous year.The company targets a 15-20% sales growth for the Bathware business in FY27.Composite Scheme of Arrangement for demerger and separate listing of business units has received stock exchange approvals and is pending with NCLT.
👀 கவனிக்க வேண்டியவை
Investors should track the NCLT approval process for the demerger, which is expected to unlock value through separate listings. The significant margin expansion in the Bathware segment and the guidance for 15-20% growth in FY27 suggest strong fundamental momentum.
Share India Securities Recommends Re. 0.50 Dividend and Early Redemption of 9,990 NCDs
Share India Securities has announced its audited financial results for the fiscal year ended March 31, 2026, alongside a final dividend recommendation of Re. 0.50 per share. A significant highlight is the board's approval for the early redemption of 9,990 secured, listed Non-Convertible Debentures (NCDs) issued in June 2025. This move to retire debt early suggests a strong liquidity position and intent to reduce interest burdens. The auditors have provided an unmodified opinion on the financial statements, indicating healthy reporting standards.
முக்கிய அம்சங்கள்
Recommended a final dividend of Re. 0.50 per equity share (25% of face value Rs. 2)Approved early redemption of 9,990 Secured, Listed, Rated, Taxable NCDsRedemption includes 5,000 Series A and 4,990 Series B debentures issued on June 23, 2025Auditors issued an unmodified opinion for both Standalone and Consolidated FY26 resultsConfirmed full compliance with security cover and utilization of NCD proceeds
👀 கவனிக்க வேண்டியவை
Investors should take the early debt redemption as a positive signal of cash surplus and balance sheet strength. The dividend provides a modest yield, but the focus should remain on the company's operational growth in the brokerage and fintech space.
Hindware Home Innovation FY26: Revenue Flat at ₹2,510 Cr, Net Loss Narrows to ₹39.3 Cr, No Dividend
Hindware Home Innovation reported a marginal 0.5% decline in consolidated revenue to ₹2,510.28 crore for the financial year ended March 31, 2026. While the company remained loss-making with a net loss of ₹39.31 crore, this was a significant narrowing from the ₹68.77 crore loss reported in FY25. Operational performance showed strength as EBITDA grew 26.7% to ₹232.52 crore, though bottom-line results were weighed down by ₹52.58 crore in exceptional items. Due to the continued losses, the Board has not recommended any dividend for FY26.
முக்கிய அம்சங்கள்
Consolidated Revenue for FY26 stood at ₹2,510.28 crore versus ₹2,522.99 crore in FY25.EBITDA increased significantly to ₹232.52 crore from ₹183.55 crore in the previous year.Net loss narrowed to ₹39.31 crore compared to a loss of ₹68.77 crore in FY25.Building Products segment contributed ₹2,193.40 crore in revenue with an EBIT of ₹117 crore.Consumer Appliances segment reported an EBIT loss of ₹1.27 crore on revenue of ₹318.07 crore.
👀 கவனிக்க வேண்டியவை
Investors should focus on the improving EBITDA margins and the narrowing net loss, while monitoring the turnaround progress in the Consumer Appliances segment. The decision to skip dividends reflects a need to conserve capital amidst ongoing restructuring or exceptional costs.
Hindware Home Innovation FY26: EBITDA Grows 27% to ₹233 Cr; Reports Net Loss of ₹39 Cr
Hindware Home Innovation reported a marginal 0.5% decline in consolidated revenue to ₹2,510.28 crore for FY26. Despite the revenue stagnation, EBITDA saw healthy growth of 26.7%, rising to ₹232.52 crore from ₹183.55 crore in the previous year. However, the company reported a consolidated net loss of ₹39.31 crore, though this was an improvement over the ₹68.77 crore loss in FY25. The board has decided not to recommend any dividend for the fiscal year.
முக்கிய அம்சங்கள்
Consolidated Revenue from operations stood at ₹2,510.28 crore for FY26, down slightly from ₹2,522.99 crore in FY25.EBITDA from continuing operations increased significantly to ₹232.52 crore compared to ₹183.55 crore in the prior year.Reported a consolidated net loss of ₹39.31 crore for FY26, impacted by exceptional items totaling ₹52.58 crore.Building products segment revenue grew to ₹2,193.40 crore, while the consumer appliances segment saw a decline to ₹318.07 crore.The Board did not recommend any dividend for the financial year ended March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to translate strong EBITDA growth into bottom-line profitability by managing exceptional costs. The improvement in operating margins is positive, but the lack of top-line growth in the consumer appliances segment warrants a cautious outlook.
Religare Enterprises FY26 Income Hits ₹8,493 Cr; Announces Demerger for Health Insurance Focus
Religare Enterprises reported a consolidated total income of ₹8,493 crores for FY26, driven by its health insurance subsidiary, Care Health, which crossed the ₹10,000 crore GWP milestone. The company has approved a demerger to separate its lending and broking businesses into Religare Finvest (RFL), leaving REL as a pure-play health insurance holding company. The Burman Group has increased its stake to 30.3% and committed ₹750 crores in capital. While the insurance segment remains robust with a 24% growth in GWP, the housing finance segment reported a loss of ₹18.6 crores for the year.
முக்கிய அம்சங்கள்
Consolidated total income for FY26 reached ₹8,493 crores with a reported PAT of ₹73.16 crores.Care Health Insurance GWP grew 24% to ₹11,417 crores, with retail health growing at 34%.Approved demerger will provide shareholders 1 share of RFL for every 1 share of REL held to unlock value.Religare Finvest (RFL) reported a profit of ₹89 crores in Q4 FY26 with ₹591 crores in cash reserves.Promoter (Burman Group) stake increased to 30.3% following a ₹750 crore capital commitment.
👀 கவனிக்க வேண்டியவை
Investors should consider the demerger as a significant value-unlocking event for the high-growth health insurance business. Monitor the progress of regulatory approvals for the demerger and the stabilization of the housing finance subsidiary.
Waaree Renewable Bags 350MW/1400MWh BESS EPC Order from Group Company
Waaree Renewable Technologies has secured a major turnkey EPC contract for a 350MW/1400MWh Battery Energy Storage System (BESS). The project includes two years of operation and maintenance services and is scheduled for completion within the financial year 2026-27. While the order is from a group entity, Waaree Forever Energies Private Limited, it is stated to be on an arm's length basis. This win significantly strengthens the company's portfolio in the high-growth energy storage segment.
முக்கிய அம்சங்கள்
Turnkey EPC contract for a massive 350MW/1400MWh grid-connected BESS projectIncludes 2 years of comprehensive operation and maintenance (O&M) servicesProject execution is slated for completion during the financial year 2026-27Contract awarded by domestic group entity Waaree Forever Energies Private Limited
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive expansion into the energy storage market, though they should monitor execution timelines and the margins associated with related-party contracts.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
